Cargando…
Dovitinib enhances temozolomide efficacy in glioblastoma cells
The multikinase inhibitor and FDA‐approved drug dovitinib (Dov) crosses the blood–brain barrier and was recently used as single drug application in clinical trials for GB patients with recurrent disease. The Dov‐mediated molecular mechanisms in GB cells are unknown. We used GB patient cells and cell...
Autores principales: | Thanasupawat, Thatchawan, Natarajan, Suchitra, Rommel, Amy, Glogowska, Aleksandra, Bergen, Hugo, Krcek, Jerry, Pitz, Marshall, Beiko, Jason, Krawitz, Sherry, Verma, Inder M., Ghavami, Saeid, Klonisch, Thomas, Hombach‐Klonisch, Sabine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537714/ https://www.ncbi.nlm.nih.gov/pubmed/28500786 http://dx.doi.org/10.1002/1878-0261.12076 |
Ejemplares similares
-
C1q/TNF‐related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma
por: Thanasupawat, Thatchawan, et al.
Publicado: (2018) -
Novel CTRP8‐RXFP1‐JAK3‐STAT3 axis promotes Cdc42‐dependent actin remodeling for enhanced filopodia formation and motility in human glioblastoma cells
por: Glogowska, Aleksandra, et al.
Publicado: (2021) -
Mechanisms of Therapeutic Resistance in Cancer (Stem) Cells with Emphasis on Thyroid Cancer Cells
por: Hombach-Klonisch, Sabine, et al.
Publicado: (2014) -
Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes
por: Thanasupawat, Thatchawan, et al.
Publicado: (2021) -
RXFP1 is Targeted by Complement C1q Tumor Necrosis Factor-Related Factor 8 in Brain Cancer
por: Thanasupawat, Thatchawan, et al.
Publicado: (2015)